基于TOPSIS法建立注射用齐拉西酮药物利用评价标准及其应用结果分析

Evaluation criteria of ziprasidone for injection and analysis of its application results based upon TOPSIS method

目的:基于TOPSIS法建立注射用齐拉西酮药物利用评价(DUE)标准,评价其临床使用合理性。方法:以注射用齐拉西酮药品说明书为基础,参考相关指南和专家共识,通过专家咨询法建立注射用齐拉西酮DUE标准,同时采用加权TOPSIS法回顾性分析安徽省精神卫生中心2022年1—12月使用注射用齐拉西酮的归档病例进行合理性评价。结果:共纳入269份病例,完全符合评价标准仅31例(11.52%),注射用齐拉西酮不合理应用常见于超适应证(46.47%)、禁忌证(0.37%)、用药疗程(9.29%)、辅助检查及实验室检查(32.71%)、药物相互作用(13.01%)、特殊人群(2.97%)和药物序贯(7.06%)。结论:所建立的注射用齐拉西酮DUE标准可用于注射用齐拉西酮临床合理性评价。

OBJECTIVE To establish the drug use evaluation(DUE)criteria for ziprasidone for injection based upon technique for order preference by similarity to an ideal solution(TOPSIS)method for evaluating the rationality of its clinical use.METHODS Based upon the drug instructions of Ziprasidone for injection,the DUE standard for ziprasidone for injection was established by referring to the relevant guidelines and expert consensus through consultations.Also weighted TOPSIS method was employed for retrospectively reviewing the archived cases of ziprasidone for injection at Anhui Mental Health Center from January to December 2022 for rationality evaluation.RESULTS A total of 269 cases were included and only 31(11.52%)fully fulfilled the evaluation criteria.Irrational use of ziprasidone for injection was common in off-label(46.47%),contraindications(0.37%),dosing course(9.29%),auxiliary and laboratory examinations(32.71%),drug interaction(13.01%),special population(2.97%)and drug sequence(7.06%).CONCLUSION The established ziprasidone for injection DUE standard may be used for clinical use of ziprasidone for injection.